Jerry Feitelson

Specialized IP licensing to institutions using agricultural biotechnology, including academic, commercial & non-profit.

• Provided strategic advice to genomics, genome editing, and farming companies, enhancing their operational effectiveness. • Conducted comprehensive program and project reviews to identify areas for improvement and growth. • Offered sales support and market insights, facilitating informed decision-making for clients. • Fostered networking opportunities that connected startups with potential partners and investors. • Developed intellectual property in genome editing

Agribody Technologies, Inc. was acquired by Global Clean Energy Holdings after a long-standing business relationship between the two companies. By combining ATI’s genetics, genomics, and plant breeding skills with GCEH’s breeding and agricultural deployment experience, the combined research team can focus on the further development of enhanced varieties of Camelina and crops with enhanced production, greater tolerance to stress, and longer shelf life. These critical traits will have important impacts on reducing food waste.

ATI applies a proven solution to food-sourcing problems due to ever-growing population, decreasing farmland availability, and climate change by increasing crop yields by at least 20% and extending shelf life of perishable products by 3-4x. Our broadly patent-protected technology modifies a fundamental genetic switch in crop plants, that also delays onset of plant senescence while increasing resistance to diseases and sublethal stresses such as drought, heat, cold, salt, low nutrients and crowding. Our technology and business model will significantly contribute to: o Increased Food Security; and o Increased Agricultural Resilience / Sustainability

Defined needs and implemented research programs for the company in the areas of genetics/breeding, horticulture & agronomics. Drafted clear business-based research programs with scope, schedule and budget. Prioritized research programs based upon the needs of the company. Raised funds for research. Developed clear lines of delineation between the research programs of the company and the non-profit 501(c)(3) Center for Sustainable Energy Farming. Wrote an overall research program for the Center to help obtain funding.

Managed the external collaborations in the CE/CEQ/Bioseparations (Discovery) Business Center. Coordinated with Product Managers, Senior Management, Legal and Finance. Set collaboration priorities; ensured that required payments were made on schedule, and contractually required business meetings held on time. Understood key aspects of the company’s Intellectual Property portfolio relating to the Business Center. Found licensing opportunities for issued patents. Monitored possible infringements of the company’s IP and coordinated with Legal for enforcement actions or licensing opportunities.

Managed commercialization of new and existing proteome fractionation and partitioning technology at Beckman Coulter, accountable for global P&L. Responsible for new opportunity/technology assessment. Managed external scientific business center alliances. Acted as a functional representative of the Business Center on program and product support teams. Developed positioning and pricing strategies, as well as commercialization and launch plans. Worked closely with market research and financial groups to assess business trends. Evaluated and prepared competitive analyses to leverage potential business opportunities. Supported the Global Commercial Marketing and Sales organizations in the commercialization of Proteomics solutions. 1 publication.

Member of the senior management team at GenWay Biotech. Responsible for strategic relationships, intellectual property, marketing and sales of innovative IgY (avian antibody)-based products and services. Established several collaborations, and lead a team to develop a series of novel proteomics sample preparation and immunoprecipitation products, resulting in a $9Mil, 5 year deal with a major company. Spearheaded many distributor & OEM relationships, involved in M&A activities. Developed and executed contracts, determined pricing of products & services, responsible for >150 client relationships, >40% of sales. 8 publications and 2 U.S. patent applications.

Responsible for all technical/scientific interactions between GBF, its Research Partners (CropDesign, Athenix, Cibus Genetics, Agrobios) and prospective international chemical company partners. Restored and expanded strategic relationships, recruited consultants, drafted research proposals and structured deals. Involved in fund-raising and capitalizing the company.

Led interdisciplinary teams to generate and present many “Green Biofactory” research proposals: metabolic pathway engineering to produce fine and specialty chemicals in plants. Recruited world-class consultants, developed novel approaches, timelines, benchmarks, budgets, markets and business models. Drafted technical parts of new Business Plan outlining Akkadix’s redirected research focus. Spearheaded acquisition of new lab and office space. Led Akkadix research teams to develop novel methods for transgenic control of plant parasitic nematodes, Plant Transformation and DNA Sequencing. Set up highly effective discovery programs, and established academic and NGO collaborations. 4 U.S. Patent applications.

Led internal group and established an extensive network of ~25 external collaborations to control plant parasitic nematodes, including discovery of nematicidal Bacillus thuringiensis (Bt) toxin genes and development of “soft chemical” applications. Company-wide coordinator of plant parasitic nematode R&D, including portions of $51 Mil collaboration with Pioneer Hi-Bred International. Served as primary Mycogen technical program manager for several strategic corporate partnerships and collaborations. Did strategic planning and was a consultant for Regulatory Affairs. Founding member of international nomenclature committee on Bt toxins. Directed Department of Molecular Biology with annual budget >$1 Mil: 21 researchers in 5 departments. Discovered and commercialized biological pesticides based on Bt toxins. Increased research efficiency between 6- and 30-fold while resources were reduced over 30%. 9 publications, 8 U.S. Patents and 1 U.S. Patent application.